Meiragtx Holdings Plc MGTX

$10.79 +0.13 (1.22%)

Valuation

Market cap
1,023,818,000
Revenue TTM
$81,390,000
Net income TTM
$-114,200,000
PE ratio
15.49
Forward PE
36.97
Profit margin
-140.31%
Debt to equity
0.46

Trading

Volume
820,000
Avg volume
772,628
Day's range
$10.65 – $11.00
Shares out
96,043,000
Stochastic %K
9%
Beta
1.35
Analysts
Strong Sell
Price target
$27.75

Price

Company profile

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as...

Show more

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
646 860 7985
Website
https://www.meiragtx.com
Address
655 Third Avenue, Suite 1115, New York, United States

Latest news

Stocktwits

MGTX Oct 2, 4:16 AM
$MGTX anyone worried about the very few participants for Xerostomia? I think only 24.
1 replies
Bogy99 Oct 1, 7:04 PM
$MGTX adding
0 replies
Bogy99 Sep 30, 1:38 PM
$MGTX been here a long time and have a sizable position already. But adding this morning on the weaker PCE. I think now October hike off the table and we should reclaim our upward trajectory. I feel good about both of our late stage programs and think this stock is extremely compelling at this valuation.
4 replies
ErnieWorthing84 Sep 29, 1:32 PM
$MGTX QURE 🫤
2 replies
slinghook67 Sep 25, 12:03 PM
$MGTX Interesting release this a:m that new Board member Alan Sebulsky acquired 34,500 MeiraGTx shares via his investment vehicle Apothecary Capital. In addition to him receiving 100,000 RSU's via his appointment to the Board. Strong conviction.......
2 replies
Bogy99 Sep 24, 5:23 PM
$MGTX the whole sector has been destroyed the last couple of weeks. We actually have hung in there quite well (headed into this week). While I don’t believe we are in a prolonged hiking environment , bio’s are paying the price for this way of thinking. Longest duration paying the price. Just need to hunker down until sky clears. I don’t believe this weeks sell off has anything to do with Amgen or Beacon. As a matter of fact , I feel strongly we get XLRP across the finish line (all secondary endpoints met!). So many irons in the fire here. Don’t lament about getting in and out. Just stay the course and good things will happen. They already are.
1 replies
dgbio Sep 24, 2:47 PM
$MGTX "The firm says the Beacon data provides important readthrough to MeiraGTx’s similar gene therapy bota-vec... Raymond James notes the FDA has given buy-in to using low level visual acuity as the primary endpoint and basis for approval in the Beacon data. The firm believes this highly derisks MeiraGTx submitting bota-vec to the FDA with the same data." https://www.investing.com/news/analyst-ratings/raymond-james-stays-bullish-on-meiragtx-stock-after-rival-data-93CH-4913464
0 replies
MGTX Sep 24, 2:15 PM
$MGTX i’m like Charlie Brown with the football. Every time MGTX hits a new high I tell myself I should sell a bit. I never do because I’m always thinking. Finally the value is gonna get recognized. Hopefully, we stay above 10 since we’re effectively dead money until the middle of next year.
1 replies